- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01989026
A Randomized Trial of Providing BCG Vaccination Immediately
Reducing Mortality at the Neonatal Intensive Care Unit in Guinea-Bissau: A Randomized Trial of Providing BCG Vaccination Immediately
Study Overview
Detailed Description
Observational studies in high-mortality areas have shown that the BCG vaccine is associated with marked benefits in child survival. These results cannot be explained by prevention of tuberculosis, which is rare during the firsts years of life. These observations have recently been tested at the Bandim Health Project (BHP) in Guinea-Bissau in randomized trials among low birth weight (LBW, <2500 g) children. According to local practice, BCG is typically postponed in LBW infants until 4-6 weeks of age. Results showed that providing BCG at the time of discharge from the hospital compared with BCG later reduced neonatal mortality by more than 40%. The protective effect started already within the first three days. Based on verbal autopsies, BCG protected the children against neonatal septicemia and pneumonia. Recent immunological studies have indicated that BCG induces epigenetic changes which reprogram the innate immune system to increased pro-inflammatory responses against unrelated pathogens; hence, BCG may indeed have a non-specific beneficial effect protecting against other infections.
BCG is recommended at birth by the World Health Organization (WHO), but is rarely given immediately at birth. In Guinea-Bissau, at the National Hospital's maternity ward, children are currently vaccinated at discharge. For children who are born healthy, this usually means 1-2 days after the delivery. However, very small children and ill children are admitted to the neonatal intensive care unit (NICU), and often stay there for days to weeks before they are discharged - and only receive BCG at the time of discharge. The mortality among children in the NICU is alarmingly high - it was 14% (254/1877) among children admitted to the NICU from November 2007 to May 2013 (unpublished data). A substantial number of children that died had normal birth weight and high Apgar scores. In most cases the underlying cause of death was infectious diseases, which could potentially be affected by BCG vaccination. Hence, the present aim is to conduct a randomized trial at the NICU to study the effect of providing BCG immediately (intervention group) versus BCG at discharge (control group). The primary outcome will be mortality during hospital stay, with cause of death, growth and length of stay as secondary outcomes.
HYPOTHESIS
Providing BCG vaccination upon admission to newborn children in the NICU incubators, rather than at discharge, is associated with 40% reduction in mortality at the NICU for children weighing >1250 g.
METHODS
Setting
The randomized trial will be conducted by the Bandim Health Project in Guinea-Bissau, at the NICU at the National Hospital Simão Mendes. The Bandim Health Project (BHP) maintains a health and demographic surveillance system (HDSS) in six suburban districts of the capital of Guinea-Bissau and covers approximately 102,000 inhabitants. All houses in the study area are visited monthly to register new pregnancies and births. All children below 3 years of age are followed through home visits every third month. The National Hospital where many women from the study area give birth is a few kilometers away. The BHP has worked at the hospital's maternity ward for many years, conducting trials of different health interventions and other observational studies to reduce infant mortality.
Study design
Children will be randomly allocated (1:1) to BCG at admission or at discharge (as per current standard of care).
Enrolment procedures
The BHP team is present at the maternity ward every day. The team will visit the NICU and identify children admitted since their last visit. The mother will have the study explained in the local language (Portuguese Creole), and also receive a written explanation in Portuguese. She will be briefly interviewed about background factors (education, previous deliveries, etc.). Anthropometric measures will be obtained and a Ballard score assessed by a trained nurse.
Randomization
Provided consent, the mother will draw a lot which indicates if the child will receive BCG immediately or BCG at discharge as usual. To ensure equal distribution of different categories of children and calendar time, randomization will be done in blocks within two groups of children; a) children at the NICU who are in an incubator (most severely ill); b) children at the NICU who are not in incubator (less ill, including also children born by caesarean section whose mother is indisposed). Randomization will further be stratified by sex and weight group (1250-1499g, 1500-1999g, 2000-2499g, 2500+ g) in blocks of 16.
Intervention
Immediately after randomization, children who were allocated to BCG vaccine will be vaccinated intradermally with 0.05 ml BCG vaccine (Statens Serum Institute, Denmark). The control group will receive BCG at discharge. All children will receive oral polio vaccine (OPV) at the time of BCG vaccination.
The study is therefore testing BCG+OPV at admission to the NICU (intervention arm) vs. BCG+OPV at discharge from NICU (control arm). Same-sex twin pairs will receive the same treatment.
Blinding
The BHP team will be in charge of randomization and vaccination. These procedures will take place without the participation of the NICU staff. BCG vaccination leaves a small mark on the skin of the child, which vanishes quickly, leaving no sign until a papule is formed several weeks later. To further ensure blinding of hospital staff, a small gauze patch will be placed over the injection site in both groups, for the entire hospital stay.
Follow-up
-At the hospital
The BHP team will visit the NICU every day and ascertain the vital status of all enrolled children and that the plasters have not been removed. All clinical and biological parameters registered by the NICU staff, including weight, temperature and respiratory frequency will also be recorded. The main outcome is survival during the stay at the NICU.
-After discharge
At the day of discharge, the BHP team will assure that all children randomised to the control group receive BCG and OPV before leaving the hospital. The children being discharged will be offered transport to their home. All included children included from Bissau will be followed for adverse events, survival, growth and morbidity with home visits after 3 days, 2 months, 6 months and 12 months of age.
-Statistical analysis
The mortality data will be analyzed in Cox proportional hazards models. Due to the expected high number of twins, all analyses will be adjusted for interdependency between twins. We will analyze the overall effect of BCG on survival, and by cause of death. Length of stay and weight gain at discharge among surviving children will be analyzed using linear regression. To prevent bias which could arise if BCG was particularly beneficial for survival among the smallest children, control and intervention children will be matched based on birth weight, and pairs of children in which one child dies will be excluded from the analysis. There will be a natural variation in the time from birth to enrolment into the trial. All analyses will be adjusted for time from birth to enrolment. All analyses will be conducted stratified by weight group, sex and season (dry (Dec-May) vs rainy (June-Nov)), since we have previously observed that both factors may modify the response to BCG and other vaccines. It is a secondary hypothesis that the early effect is strongest for boys and in the dry season.
Public health campaigns which also affect newborn children, for example polio vaccination campaigns, could interfere with the trial. If such campaigns are implemented also for children in the ICU, the children will be censored in the analysis at the time of the intervention. Likewise if there are strikes, shortage of electricity or other events which interfere with the health services, the children will censored in the analysis after discussion with the DSMB.
-Sample size
The NICU admits around 350-400 children per year who are placed in the incubators. Around 94% weigh more than 1250 g. The median length of stay is 6 days. With a mortality of 12%, we would need to enroll 1262 children to detect a 40% difference in mortality between BCG-vaccinated and BCG-unvaccinated children with 80% power and a significance level of 5%. This corresponds to 122 deaths. If mortality declines (as it has done over the last years in the BHP study area), the event number would have to be slightly higher; with a mortality of 11% we would need to continue to 123 deaths to maintain the same power; if it declines to 10% it would be 124 deaths, etc.
Based on this data, the investigators expect to reach the needed number of events during a period of 4 years, taking into account that some children will have died before they can be enrolled and some children will be too ill to be enrolled.
ETHICAL CONSIDERATIONS The study protocol has been approved by The Danish Central Ethical Committee and the National Ethical Committee in Guinea-Bissau. The trial will be registered at clinicaltrials.gov. In previous studies BCG was safe for LBW children and even more beneficial among the smallest children. A local clinical monitor and a Data Safety and Monitoring Board (DSMB) will be appointed.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bissau, Guinea-Bissau, 1004
- Maternity Ward, National Hospital Simao Mendes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children admitted to the neonatal intensive care unit
Exclusion Criteria:
- Birth weight<1250 g
- Apgar score<2
- Moribund children and children with gross malformations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BCG at admission to NICU
These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
|
|
No Intervention: BCG at discharge (as usual)
These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days.
|
Participants will be followed for the duration of hospital stay, an expected average of 6 days.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of admission
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days
|
Participants will be followed for the duration of hospital stay, an expected average of 6 days
|
Cause of death
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days.
|
Participants will be followed for the duration of hospital stay, an expected average of 6 days.
|
Growth
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days.
|
Participants will be followed for the duration of hospital stay, an expected average of 6 days.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Morten Bjerregaard-Andersen, MD, PhD, Research Center for Vitamins and Vaccines
- Study Director: Christine Stabell Benn, MD, PhD, DMSc, Research Center for Vitamins and Vaccines
- Study Director: Peter Aaby, Prof, DMSc, Bandim Health Project
Publications and helpful links
General Publications
- Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, Diness BR, Lausch KR, Lund N, Biering-Sorensen S, Whittle H, Benn CS. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011 Jul 15;204(2):245-52. doi: 10.1093/infdis/jir240.
- Schaltz-Buchholzer F, Berendsen M, Roth A, Jensen KJ, Bjerregaard-Andersen M, Kjaer Sorensen M, Monteiro I, Aaby P, Stabell Benn C. BCG skin reactions by 2 months of age are associated with better survival in infancy: a prospective observational study from Guinea-Bissau. BMJ Glob Health. 2020 Sep;5(9):e002993. doi: 10.1136/bmjgh-2020-002993.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CVK-2013-1303771
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Neonatal Mortality
-
Eunice Kennedy Shriver National Institute of Child...United States Agency for International Development (USAID); Bill and Melinda...CompletedNeonatal MortalityUnited States, Nepal
-
Aga Khan UniversityUnited States Agency for International Development (USAID); Population Council and other collaboratorsCompletedMaternal Mortality | Neonatal Mortality | Early Postpartum and Newborn CarePakistan
-
The Hospital for Sick ChildrenAga Khan University; Grand Challenges Canada; March of Dimes; UBS Optimus Foundation and other collaboratorsCompleted
-
The Hospital for Sick ChildrenAga Khan University; Grand Challenges Canada; March of DimesCompleted
-
The Hospital for Sick ChildrenAga Khan University; Aga Khan Health Services; The Aga Khan FoundationRecruiting
-
London School of Hygiene and Tropical MedicineInstitute of Child Health; Kintampo Health Research Centre, GhanaCompleted
-
Bandim Health ProjectMarch of Dimes; DanidaCompletedMortality | Growth | Morbidity | Neonatal MortalityGuinea-Bissau
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Annamalai University; Ministry of Health and...CompletedOmphalitis | Neonatal Mortality | Cord CareTanzania
-
Central Hospital, Nancy, FranceNot yet recruitingHospitalization | Neonatal Period | Early Maternity Discharge | Risk Factor Readmission
Clinical Trials on BCG
-
Bandim Health ProjectUniversity of Southern DenmarkRecruitingMorbidity;Newborn | Non-specific Effects of Vaccines | Death, Infant | Morbidity;Infant | Death; NeonatalGuinea-Bissau
-
Bandim Health ProjectOdense University Hospital; Odense Patient Data Explorative Network; Municipality...CompletedCovid19 | Immunosenescence | Vaccine Preventable Disease | Morbidity | Non-specific Effects of Vaccines | Heterologous ImmunityDenmark
-
AerasUniversity of RochesterCompleted
-
Bandim Health ProjectResearch Center for Vitamins and Vaccines, Statens Serum InstituteTerminatedInfant Mortality | BCGGuinea-Bissau
-
ImmunityBio, Inc.RecruitingNon-muscle Invasive Bladder CancerUnited States
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; University of Melbourne; Mercy Hospital for Women,...Active, not recruitingRespiratory Tract Infections | Allergy | EczemaAustralia
-
Biofabri, S.LSouth African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative and other collaboratorsCompletedTuberculosisSouth Africa
-
Bandim Health ProjectResearch Center for Vitamins and VaccinesCompletedVaccine Adverse Reaction | Vaccine Reaction | Infant Mortality | Heterologous Immunity | Infant Morbidity | Trained ImmunityGuinea-Bissau
-
Chengdu CoenBiotech Co., LtdHunan Cancer HospitalCompleted
-
Chengdu CoenBiotech Co., LtdSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting